方法进展说明:试点随机对照试验。

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-04-24 DOI:10.1002/jhm.13376
Amanda Corley RN PhD, Nicole Marsh RN PhD, Samantha Keogh RN PhD
{"title":"方法进展说明:试点随机对照试验。","authors":"Amanda Corley RN PhD,&nbsp;Nicole Marsh RN PhD,&nbsp;Samantha Keogh RN PhD","doi":"10.1002/jhm.13376","DOIUrl":null,"url":null,"abstract":"<p>Definitive randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine but can be complicated, protracted, and expensive. Given the challenges of large-scale trials, pilot trials serve as a crucial initial step, allowing for refinement and validation before embarking on the definitive RCT.<span><sup>1</sup></span> They are a crucial element of good study design and, while conducting a pilot RCT does not guarantee success of the definitive RCT, it increases the likelihood of successful trial completion.<span><sup>2</sup></span> More than US$100 billion is invested annually in biomedical research but often this research is conducted wastefully from poor study design and/or study procedures.<span><sup>3</sup></span> Conducting a well-designed pilot RCT before launching an expensive, time-consuming definitive trial can minimize research waste and improve study conduct.</p><p>Small RCTs cannot be branded pilot or feasibility trials to justify a small sample size. Pilot RCTs have a very specific purpose and inform future trial conduct.<span><sup>4</sup></span> Indeed, research models, including the Canadian Critical Care Trials Group programmatic model, the UK Medical Research Council, and the Australian Clinical Trials Alliance, highlight the importance of pilot RCTs as an integral and necessary step in interventional clinical research (Figure 1). Early piloting of research methods and interventions is important in evaluating feasibility and acceptability before the definitive RCT.</p><p>The importance of pilot trials has been acknowledged for decades<span><sup>5</sup></span> with trial methods evolving over time. It is within this context that we will discuss pilot RCTs used to inform larger definitive RCTs. We will situate pilot trial methods within a larger research framework and propose important concepts in design and reporting.</p><p>The terms “pilot” and “feasibility” trial are used interchangeably by some, but others purport that each type of trial has unique characteristics and therefore define them separately. Whitehead et al.<span><sup>4</sup></span> proposed that pilot trials are a type of feasibility trial with some distinguishing elements: (i) stricter methodology (closely following the definitive study design); (ii) intended to lead to further work; (iii) a smaller version of the larger study; and (iv) focuses on trial processes. This delineation suggests that a pilot RCT is a specific subset of feasibility trial. Henceforth, we adopt the term “pilot.”</p><p>Pilot RCTs allow researchers to test and establish feasibility of the study protocol, study processes, data collection, and intervention fidelity and acceptability.<span><sup>2, 4, 6</sup></span> Table 1 details trial elements tested by a pilot RCT.</p><p>An important indicator of trial feasibility is the ability to recruit the required numbers of participants, using inclusion/exclusion criteria, from the sample population. Recruitment to RCTs can be challenging and investigators are frequently unable to achieve the predetermined participant numbers.<span><sup>6</sup></span> Investigators' over-estimation of the size of the pool from which to sample ultimately leads to under-recruitment, negates the trial's ability to answer the proposed research question/s, wastes resources and can be unethical, and often results from foregoing a rigorous pilot trial process. Funders also value the importance of testing feasibility before embarking on definitive RCTs. For example, in criteria from the National Health and Medical Research Council of Australia, research projects must be “highly feasible with all required techniques and resources established.”</p><p>Traditionally, pilot RCTs have been separate (i.e., external) to the definitive RCT. External pilot RCTs are a stand-alone trial completed before the definitive RCT: data are analyzed, results are generated, and thus inform feasibility of progressing to a definitive trial.<span><sup>7</sup></span> External pilot RCTs are particularly useful if uncertainties exist around intervention fidelity or novel trial aspects (such as new clinical settings).<span><sup>8</sup></span> However, data from external pilot RCTs are not included in the larger trial, published separately and therefore could be seen as “wasted.”<span><sup>4</sup></span> Furthermore, attracting funding for external pilot RCTs may be difficult, particularly when study outcomes are unrelated to patient benefit, but rather focus on feasibility.</p><p>Over the last decade, more researchers are using internal or embedded pilot RCTs as an innovative and efficient way to assess protocol and intervention feasibility and acceptability.<span><sup>9</sup></span> Cooper et al. suggest this is useful when overall feasibility has largely been established, and evidence on recruitment, randomization, and attrition rates are required.<span><sup>10</sup></span> Internal pilot RCTs are a phase within the definitive RCT and planning occurs alongside the main trial. Clear prespecified progression criteria (see upcoming section) are used to determine progression to a definitive RCT,<span><sup>9</sup></span> with this decision ideally made by an external panel. If appropriate, and no significant changes are required to outcome definitions or interventions, participants' data from the internal pilot can be used in the final analysis of the definitive trial.<span><sup>8</sup></span> Advantages include seamless integration into the definitive trial, ability to make real-time adjustments and efficiency through minimizing duplication and optimizing resources.<span><sup>9</sup></span></p><p>Kleidon et al.<span><sup>14</sup></span> use these criteria in their external pilot to determine the feasibility of a larger-scale RCT. In this case, all feasibility criteria were met, and the trial progressed to a definitive RCT<span><sup>18</sup></span> (Table 2). Feasibility targets will be highly individual from study to study and must consider factors such as funding, number of recruiting sites, and incidence of the condition being studied.</p><p>Clear guidance on reporting pilot RCTs is provided in the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement: extension to randomized pilot and feasibility trials<span><sup>1</sup></span> which utilizes checklists for study abstract and body and a template flowchart to improve transparency and quality of reporting. The CONSORT statement mentions that, while it does not apply specifically to internal pilot RCTs, it may be applicable or modifiable in part for internal pilot RCTs. It is important to register pilot RCTs with a Clinical Trials Registry so study design is transparent before publication, thus reducing reporting bias.<span><sup>1</sup></span> Publishing external pilot RCTs is an important step in dissemination of trial feasibility<span><sup>6</sup></span> and has been aided by the launch of <i>BioMed Central Pilot and Feasibility Studies</i> (https://pilotfeasibilitystudies.biomedcentral.com/) whose core business includes publication of pilot and feasibility studies. For definitive RCTs with an internal pilot, feasibility outcomes from the pilot phase in addition to clinical outcomes (which include data from the internal pilot if no major modifications were made to population, intervention or outcomes) would be reported.</p><p>The solid foundation provided by well-designed pilot trials is now broadly recognized. Pilot RCTs afford a preparatory phase for learning before expansion, mitigating the risk of logistical impracticalities leading to failure in subsequent large-scale RCTs. No large publicly funded RCT should be conducted without thorough piloting of interventions, study processes, and study procedures.</p><p>Amanda Corley declares her employer, on her behalf, has received unrestricted investigator-initiated research grants, from Cardinal Health, 3M, and Eloquest (unrelated to the current project) and a consultancy payment from Wolters Kluwer for review of clinical practice guidelines. Nicole Marsh declares her employer has received on her behalf speaker fees from 3M and Medline; investigator-initiated research grants from Biolife, 3M, Eloquest, and Cardinal Health; and a consultancy payment from 3M (unrelated to the current project). Samantha Keogh declares her employer, on her behalf, has received monies from BD Medical and ITL Biomedical for Educational consultancies (unrelated to the current project).</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jhm.13376","citationCount":"0","resultStr":"{\"title\":\"Methodological progress note: Pilot randomized controlled trials\",\"authors\":\"Amanda Corley RN PhD,&nbsp;Nicole Marsh RN PhD,&nbsp;Samantha Keogh RN PhD\",\"doi\":\"10.1002/jhm.13376\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Definitive randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine but can be complicated, protracted, and expensive. Given the challenges of large-scale trials, pilot trials serve as a crucial initial step, allowing for refinement and validation before embarking on the definitive RCT.<span><sup>1</sup></span> They are a crucial element of good study design and, while conducting a pilot RCT does not guarantee success of the definitive RCT, it increases the likelihood of successful trial completion.<span><sup>2</sup></span> More than US$100 billion is invested annually in biomedical research but often this research is conducted wastefully from poor study design and/or study procedures.<span><sup>3</sup></span> Conducting a well-designed pilot RCT before launching an expensive, time-consuming definitive trial can minimize research waste and improve study conduct.</p><p>Small RCTs cannot be branded pilot or feasibility trials to justify a small sample size. Pilot RCTs have a very specific purpose and inform future trial conduct.<span><sup>4</sup></span> Indeed, research models, including the Canadian Critical Care Trials Group programmatic model, the UK Medical Research Council, and the Australian Clinical Trials Alliance, highlight the importance of pilot RCTs as an integral and necessary step in interventional clinical research (Figure 1). Early piloting of research methods and interventions is important in evaluating feasibility and acceptability before the definitive RCT.</p><p>The importance of pilot trials has been acknowledged for decades<span><sup>5</sup></span> with trial methods evolving over time. It is within this context that we will discuss pilot RCTs used to inform larger definitive RCTs. We will situate pilot trial methods within a larger research framework and propose important concepts in design and reporting.</p><p>The terms “pilot” and “feasibility” trial are used interchangeably by some, but others purport that each type of trial has unique characteristics and therefore define them separately. Whitehead et al.<span><sup>4</sup></span> proposed that pilot trials are a type of feasibility trial with some distinguishing elements: (i) stricter methodology (closely following the definitive study design); (ii) intended to lead to further work; (iii) a smaller version of the larger study; and (iv) focuses on trial processes. This delineation suggests that a pilot RCT is a specific subset of feasibility trial. Henceforth, we adopt the term “pilot.”</p><p>Pilot RCTs allow researchers to test and establish feasibility of the study protocol, study processes, data collection, and intervention fidelity and acceptability.<span><sup>2, 4, 6</sup></span> Table 1 details trial elements tested by a pilot RCT.</p><p>An important indicator of trial feasibility is the ability to recruit the required numbers of participants, using inclusion/exclusion criteria, from the sample population. Recruitment to RCTs can be challenging and investigators are frequently unable to achieve the predetermined participant numbers.<span><sup>6</sup></span> Investigators' over-estimation of the size of the pool from which to sample ultimately leads to under-recruitment, negates the trial's ability to answer the proposed research question/s, wastes resources and can be unethical, and often results from foregoing a rigorous pilot trial process. Funders also value the importance of testing feasibility before embarking on definitive RCTs. For example, in criteria from the National Health and Medical Research Council of Australia, research projects must be “highly feasible with all required techniques and resources established.”</p><p>Traditionally, pilot RCTs have been separate (i.e., external) to the definitive RCT. External pilot RCTs are a stand-alone trial completed before the definitive RCT: data are analyzed, results are generated, and thus inform feasibility of progressing to a definitive trial.<span><sup>7</sup></span> External pilot RCTs are particularly useful if uncertainties exist around intervention fidelity or novel trial aspects (such as new clinical settings).<span><sup>8</sup></span> However, data from external pilot RCTs are not included in the larger trial, published separately and therefore could be seen as “wasted.”<span><sup>4</sup></span> Furthermore, attracting funding for external pilot RCTs may be difficult, particularly when study outcomes are unrelated to patient benefit, but rather focus on feasibility.</p><p>Over the last decade, more researchers are using internal or embedded pilot RCTs as an innovative and efficient way to assess protocol and intervention feasibility and acceptability.<span><sup>9</sup></span> Cooper et al. suggest this is useful when overall feasibility has largely been established, and evidence on recruitment, randomization, and attrition rates are required.<span><sup>10</sup></span> Internal pilot RCTs are a phase within the definitive RCT and planning occurs alongside the main trial. Clear prespecified progression criteria (see upcoming section) are used to determine progression to a definitive RCT,<span><sup>9</sup></span> with this decision ideally made by an external panel. If appropriate, and no significant changes are required to outcome definitions or interventions, participants' data from the internal pilot can be used in the final analysis of the definitive trial.<span><sup>8</sup></span> Advantages include seamless integration into the definitive trial, ability to make real-time adjustments and efficiency through minimizing duplication and optimizing resources.<span><sup>9</sup></span></p><p>Kleidon et al.<span><sup>14</sup></span> use these criteria in their external pilot to determine the feasibility of a larger-scale RCT. In this case, all feasibility criteria were met, and the trial progressed to a definitive RCT<span><sup>18</sup></span> (Table 2). Feasibility targets will be highly individual from study to study and must consider factors such as funding, number of recruiting sites, and incidence of the condition being studied.</p><p>Clear guidance on reporting pilot RCTs is provided in the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement: extension to randomized pilot and feasibility trials<span><sup>1</sup></span> which utilizes checklists for study abstract and body and a template flowchart to improve transparency and quality of reporting. The CONSORT statement mentions that, while it does not apply specifically to internal pilot RCTs, it may be applicable or modifiable in part for internal pilot RCTs. It is important to register pilot RCTs with a Clinical Trials Registry so study design is transparent before publication, thus reducing reporting bias.<span><sup>1</sup></span> Publishing external pilot RCTs is an important step in dissemination of trial feasibility<span><sup>6</sup></span> and has been aided by the launch of <i>BioMed Central Pilot and Feasibility Studies</i> (https://pilotfeasibilitystudies.biomedcentral.com/) whose core business includes publication of pilot and feasibility studies. For definitive RCTs with an internal pilot, feasibility outcomes from the pilot phase in addition to clinical outcomes (which include data from the internal pilot if no major modifications were made to population, intervention or outcomes) would be reported.</p><p>The solid foundation provided by well-designed pilot trials is now broadly recognized. Pilot RCTs afford a preparatory phase for learning before expansion, mitigating the risk of logistical impracticalities leading to failure in subsequent large-scale RCTs. No large publicly funded RCT should be conducted without thorough piloting of interventions, study processes, and study procedures.</p><p>Amanda Corley declares her employer, on her behalf, has received unrestricted investigator-initiated research grants, from Cardinal Health, 3M, and Eloquest (unrelated to the current project) and a consultancy payment from Wolters Kluwer for review of clinical practice guidelines. Nicole Marsh declares her employer has received on her behalf speaker fees from 3M and Medline; investigator-initiated research grants from Biolife, 3M, Eloquest, and Cardinal Health; and a consultancy payment from 3M (unrelated to the current project). Samantha Keogh declares her employer, on her behalf, has received monies from BD Medical and ITL Biomedical for Educational consultancies (unrelated to the current project).</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jhm.13376\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jhm.13376\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhm.13376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

摘要

确定性随机对照试验(RCT)是循证医学的基石,但可能会很复杂、旷日持久且费用高昂。1 试点试验是良好研究设计的关键要素,虽然进行试点试验并不能保证最终 RCT 的成功,但却能增加试验成功完成的可能性。每年用于生物医学研究的投资超过 1000 亿美元,但这些研究往往因研究设计和/或研究程序不当而造成浪费。3 在启动昂贵、耗时的最终试验之前,进行精心设计的试验性 RCT 可以最大限度地减少研究浪费,改善研究行为。4 事实上,包括加拿大重症监护试验小组计划模式、英国医学研究委员会和澳大利亚临床试验联盟在内的各种研究模式都强调了试验性 RCT 的重要性,认为它是干预性临床研究不可或缺的必要步骤(图 1)。研究方法和干预措施的早期试点对于在最终 RCT 之前评估可行性和可接受性非常重要。几十年来,随着试验方法的不断发展,试点试验的重要性已得到认可5。正是在这种背景下,我们将讨论用于为更大规模的确定性研究试验提供信息的试验性研究试验。我们将把先导试验方法置于更大的研究框架中,并提出设计和报告方面的重要概念。"先导 "和 "可行性 "试验这两个术语在一些人那里可以互换使用,但另一些人则认为每种类型的试验都有其独特性,因此要分别定义。怀特黑德等人4 提出,试验性试验是可行性试验的一种,具有一些区别要素:(i) 采用更严格的方法(严格遵循确定的研究设计);(ii) 旨在开展进一步的工作;(iii) 是大型研究的缩小版;(iv) 侧重于试验过程。这种划分表明,试验性 RCT 是可行性试验的一个特定子集。因此,我们采用 "试验 "一词。试验性 RCT 使研究人员能够测试和确定研究方案、研究过程、数据收集以及干预的忠实性和可接受性的可行性。6 研究者过高估计样本群的规模,最终导致招募不足,使试验无法回答提出的研究问题,浪费资源,而且可能不符合伦理道德,这往往是放弃严格的试点试验过程的结果。资助者也重视在开展确定性 RCT 之前测试可行性的重要性。例如,在澳大利亚国家健康与医学研究委员会的标准中,研究项目必须 "在所有必要的技术和资源都已确定的情况下,具有高度可行性"。外部试点 RCT 是在最终 RCT 之前完成的独立试验:对数据进行分析,得出结果,从而为推进最终试验的可行性提供信息。如果干预措施的忠实性或新的试验内容(如新的临床环境)存在不确定性,外部试点 RCT 尤为有用。8 但是,外部试点 RCT 的数据不包括在大型试验中,而是单独公布,因此可能被视为 "浪费"。"4 此外,外部试验性 RCT 可能很难吸引到资金,尤其是当研究结果与患者获益无关,而是侧重于可行性时。9 Cooper 等人认为,当总体可行性已基本确定,但需要有关招募、随机化和自然减员率的证据时,这种方法非常有用。10 内部试点 RCT 是最终 RCT 的一个阶段,计划与主要试验同时进行。明确的预设进展标准(见下节)用于决定是否进入最终 RCT,9 最好由外部专家小组做出决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Methodological progress note: Pilot randomized controlled trials

Definitive randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine but can be complicated, protracted, and expensive. Given the challenges of large-scale trials, pilot trials serve as a crucial initial step, allowing for refinement and validation before embarking on the definitive RCT.1 They are a crucial element of good study design and, while conducting a pilot RCT does not guarantee success of the definitive RCT, it increases the likelihood of successful trial completion.2 More than US$100 billion is invested annually in biomedical research but often this research is conducted wastefully from poor study design and/or study procedures.3 Conducting a well-designed pilot RCT before launching an expensive, time-consuming definitive trial can minimize research waste and improve study conduct.

Small RCTs cannot be branded pilot or feasibility trials to justify a small sample size. Pilot RCTs have a very specific purpose and inform future trial conduct.4 Indeed, research models, including the Canadian Critical Care Trials Group programmatic model, the UK Medical Research Council, and the Australian Clinical Trials Alliance, highlight the importance of pilot RCTs as an integral and necessary step in interventional clinical research (Figure 1). Early piloting of research methods and interventions is important in evaluating feasibility and acceptability before the definitive RCT.

The importance of pilot trials has been acknowledged for decades5 with trial methods evolving over time. It is within this context that we will discuss pilot RCTs used to inform larger definitive RCTs. We will situate pilot trial methods within a larger research framework and propose important concepts in design and reporting.

The terms “pilot” and “feasibility” trial are used interchangeably by some, but others purport that each type of trial has unique characteristics and therefore define them separately. Whitehead et al.4 proposed that pilot trials are a type of feasibility trial with some distinguishing elements: (i) stricter methodology (closely following the definitive study design); (ii) intended to lead to further work; (iii) a smaller version of the larger study; and (iv) focuses on trial processes. This delineation suggests that a pilot RCT is a specific subset of feasibility trial. Henceforth, we adopt the term “pilot.”

Pilot RCTs allow researchers to test and establish feasibility of the study protocol, study processes, data collection, and intervention fidelity and acceptability.2, 4, 6 Table 1 details trial elements tested by a pilot RCT.

An important indicator of trial feasibility is the ability to recruit the required numbers of participants, using inclusion/exclusion criteria, from the sample population. Recruitment to RCTs can be challenging and investigators are frequently unable to achieve the predetermined participant numbers.6 Investigators' over-estimation of the size of the pool from which to sample ultimately leads to under-recruitment, negates the trial's ability to answer the proposed research question/s, wastes resources and can be unethical, and often results from foregoing a rigorous pilot trial process. Funders also value the importance of testing feasibility before embarking on definitive RCTs. For example, in criteria from the National Health and Medical Research Council of Australia, research projects must be “highly feasible with all required techniques and resources established.”

Traditionally, pilot RCTs have been separate (i.e., external) to the definitive RCT. External pilot RCTs are a stand-alone trial completed before the definitive RCT: data are analyzed, results are generated, and thus inform feasibility of progressing to a definitive trial.7 External pilot RCTs are particularly useful if uncertainties exist around intervention fidelity or novel trial aspects (such as new clinical settings).8 However, data from external pilot RCTs are not included in the larger trial, published separately and therefore could be seen as “wasted.”4 Furthermore, attracting funding for external pilot RCTs may be difficult, particularly when study outcomes are unrelated to patient benefit, but rather focus on feasibility.

Over the last decade, more researchers are using internal or embedded pilot RCTs as an innovative and efficient way to assess protocol and intervention feasibility and acceptability.9 Cooper et al. suggest this is useful when overall feasibility has largely been established, and evidence on recruitment, randomization, and attrition rates are required.10 Internal pilot RCTs are a phase within the definitive RCT and planning occurs alongside the main trial. Clear prespecified progression criteria (see upcoming section) are used to determine progression to a definitive RCT,9 with this decision ideally made by an external panel. If appropriate, and no significant changes are required to outcome definitions or interventions, participants' data from the internal pilot can be used in the final analysis of the definitive trial.8 Advantages include seamless integration into the definitive trial, ability to make real-time adjustments and efficiency through minimizing duplication and optimizing resources.9

Kleidon et al.14 use these criteria in their external pilot to determine the feasibility of a larger-scale RCT. In this case, all feasibility criteria were met, and the trial progressed to a definitive RCT18 (Table 2). Feasibility targets will be highly individual from study to study and must consider factors such as funding, number of recruiting sites, and incidence of the condition being studied.

Clear guidance on reporting pilot RCTs is provided in the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement: extension to randomized pilot and feasibility trials1 which utilizes checklists for study abstract and body and a template flowchart to improve transparency and quality of reporting. The CONSORT statement mentions that, while it does not apply specifically to internal pilot RCTs, it may be applicable or modifiable in part for internal pilot RCTs. It is important to register pilot RCTs with a Clinical Trials Registry so study design is transparent before publication, thus reducing reporting bias.1 Publishing external pilot RCTs is an important step in dissemination of trial feasibility6 and has been aided by the launch of BioMed Central Pilot and Feasibility Studies (https://pilotfeasibilitystudies.biomedcentral.com/) whose core business includes publication of pilot and feasibility studies. For definitive RCTs with an internal pilot, feasibility outcomes from the pilot phase in addition to clinical outcomes (which include data from the internal pilot if no major modifications were made to population, intervention or outcomes) would be reported.

The solid foundation provided by well-designed pilot trials is now broadly recognized. Pilot RCTs afford a preparatory phase for learning before expansion, mitigating the risk of logistical impracticalities leading to failure in subsequent large-scale RCTs. No large publicly funded RCT should be conducted without thorough piloting of interventions, study processes, and study procedures.

Amanda Corley declares her employer, on her behalf, has received unrestricted investigator-initiated research grants, from Cardinal Health, 3M, and Eloquest (unrelated to the current project) and a consultancy payment from Wolters Kluwer for review of clinical practice guidelines. Nicole Marsh declares her employer has received on her behalf speaker fees from 3M and Medline; investigator-initiated research grants from Biolife, 3M, Eloquest, and Cardinal Health; and a consultancy payment from 3M (unrelated to the current project). Samantha Keogh declares her employer, on her behalf, has received monies from BD Medical and ITL Biomedical for Educational consultancies (unrelated to the current project).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1